# Immunoinformatics-driven multi-epitope vaccine design targeting PSMA, STEAP1, and B7H3 for prostate cancer

## TL;DR

This study uses computational methods to design a multi-epitope vaccine targeting three prostate cancer-related proteins, showing strong potential for triggering an immune response.

## Contribution

A novel multi-epitope vaccine design targeting PSMA, STEAP1, and B7H3 using an integrated immunoinformatics approach.

## Key findings

- The vaccine showed 97.51% global HLA allele coverage, indicating broad population applicability.
- It demonstrated strong binding to B-cell receptors and MHC molecules, suggesting high immunogenicity.
- Molecular dynamics simulations confirmed the vaccine's structural stability.

## Abstract

Prostate cancer remains a major global health challenge, necessitating precision immunotherapeutic strategies tailored to tumor-associated antigens. This study aimed to design a multi-epitope peptide vaccine targeting prostate-specific membrane antigen (PSMA), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and B7-H3, three biomarkers strongly associated with prostate cancer progression.

A multi-layered immunoinformatics-driven approach was employed, integrating epitope prediction, antigenicity and immunogenicity assessment, allergenicity and toxicity screening, population coverage analysis, molecular docking, and molecular dynamics simulations. Selected epitopes were assembled into a vaccine construct using appropriate adjuvants and linkers to enhance immune activation and structural stability.

The designed vaccine construct demonstrated extensive global HLA allele coverage (97.51%), strong binding affinity to B-cell receptors, MHC molecules, and favorable structural stability during molecular dynamics simulations.

These findings suggest that the proposed multi-epitope vaccine represents a promising immunotherapeutic candidate for prostate cancer and warrants further experimental validation.

This study presents a computationally designed multi-epitope peptide vaccine targeting prostate cancer-associated antigens PSMA, STEAP1, and B7H3. The top-left section illustrates the bioinformatics pipeline, including vaccine construction, molecular docking, molecular dynamics, and immune simulation analyses, which guide vaccine design. Upon administration, the vaccine is processed by antigen-presenting cells (APCs) and transported through the lymphatic system, triggering an adaptive immune response. The differentiation and proliferation of CD8+ cytotoxic T cells and CD4+ helper T cells enhance tumor recognition, while B cells produce antigen-specific antibodies. Activated cytotoxic T cells release perforin and granzymes, leading to tumor cell lysis. This immunoinformatics-driven approach supports the development of targeted prostate cancer immunotherapy with potential clinical applications. Created using BioRender.com.
Workflow infographic illustrating the multi-step computational process of vaccine design, from antigen sequence retrieval and epitope selection to structural identification, molecular docking, immune simulation, and final evaluation of a potential vaccine candidate, with labeled diagrams and analysis tools referenced throughout.

This study presents a computationally designed multi-epitope peptide vaccine targeting prostate cancer-associated antigens PSMA, STEAP1, and B7H3. The top-left section illustrates the bioinformatics pipeline, including vaccine construction, molecular docking, molecular dynamics, and immune simulation analyses, which guide vaccine design. Upon administration, the vaccine is processed by antigen-presenting cells (APCs) and transported through the lymphatic system, triggering an adaptive immune response. The differentiation and proliferation of CD8+ cytotoxic T cells and CD4+ helper T cells enhance tumor recognition, while B cells produce antigen-specific antibodies. Activated cytotoxic T cells release perforin and granzymes, leading to tumor cell lysis. This immunoinformatics-driven approach supports the development of targeted prostate cancer immunotherapy with potential clinical applications. Created using BioRender.com.